🎉 M&A multiples are live!
Check it out!

Kezar Life Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kezar Life Sciences and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Kezar Life Sciences Overview

About Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.


Founded

2015

HQ

United States of America
Employees

55

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$84.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kezar Life Sciences Financials

Kezar Life Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Kezar Life Sciences achieved revenue of n/a and an EBITDA of -$81.1M.

Kezar Life Sciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kezar Life Sciences valuation multiples based on analyst estimates

Kezar Life Sciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $7.0M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$99.3M -$81.1M XXX XXX XXX
EBITDA Margin -1418% -Infinity% XXX XXX XXX
Net Profit -$68.2M -$102M XXX XXX XXX
Net Margin -975% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kezar Life Sciences Stock Performance

As of April 15, 2025, Kezar Life Sciences's stock price is $4.

Kezar Life Sciences has current market cap of $31.6M, and EV of -$84.5M.

See Kezar Life Sciences trading valuation data

Kezar Life Sciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$84.5M $31.6M XXX XXX XXX XXX $-10.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kezar Life Sciences Valuation Multiples

As of April 15, 2025, Kezar Life Sciences has market cap of $31.6M and EV of -$84.5M.

Kezar Life Sciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Kezar Life Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kezar Life Sciences and 10K+ public comps

Kezar Life Sciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$84.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.0x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kezar Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kezar Life Sciences Valuation Multiples

Kezar Life Sciences's NTM/LTM revenue growth is n/a

Kezar Life Sciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Kezar Life Sciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kezar Life Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kezar Life Sciences and other 10K+ public comps

Kezar Life Sciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -18% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kezar Life Sciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kezar Life Sciences M&A and Investment Activity

Kezar Life Sciences acquired  XXX companies to date.

Last acquisition by Kezar Life Sciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kezar Life Sciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kezar Life Sciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kezar Life Sciences

When was Kezar Life Sciences founded? Kezar Life Sciences was founded in 2015.
Where is Kezar Life Sciences headquartered? Kezar Life Sciences is headquartered in United States of America.
How many employees does Kezar Life Sciences have? As of today, Kezar Life Sciences has 55 employees.
Who is the CEO of Kezar Life Sciences? Kezar Life Sciences's CEO is Dr. Christopher Kirk, PhD.
Is Kezar Life Sciences publicy listed? Yes, Kezar Life Sciences is a public company listed on NAS.
What is the stock symbol of Kezar Life Sciences? Kezar Life Sciences trades under KZR ticker.
When did Kezar Life Sciences go public? Kezar Life Sciences went public in 2018.
Who are competitors of Kezar Life Sciences? Similar companies to Kezar Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kezar Life Sciences? Kezar Life Sciences's current market cap is $31.6M
Is Kezar Life Sciences profitable? Yes, Kezar Life Sciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.